SMR: Society for Melanoma Research

Despite the various treatment advances in melanoma, advanced stages of the disease remain a significant challenge for oncologists. Novel methods of attacking disease vulnerabilities continue to be developed-one such technique is the use of oncolytic viruses to destroy cancer cells. A couple of studies presented an update on preclinical and clinical progress with CAVATAK, formulated using the common cold Coxsackievirus Type A21 (CVA21), during the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13—16.

Much of the news at the Society of Melanoma Research, 2014 International Congress, involves breakthrough therapies for treating metastatic melanoma in its later stages. But the year has brought developments in diagnostics, too. Tools to determine which patients need aggressive treatment and which ones do not are becoming important. As awareness of melanoma grows, more patients arrive at doctors' offices with suspicious skin marks at earlier stages.

During the first plenary session on the second day of the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13-16, Targeted Therapies: Genetics and Biology, several researchers presented their thoughts on where they see the future of melanoma research.

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo